MSC-derived small extracellular vesicles exert cardioprotective effect through reducing VLCFAs and apoptosis in human cardiac organoid IRI model

Boon Min Poh,Lee Chuen Liew,Yan Ni Annie Soh,Ruenn Chai Lai,Sai Kiang Lim,Ying Swan Ho,Boon Seng Soh
DOI: https://doi.org/10.1093/stmcls/sxae015
IF: 5.845
2024-02-23
Stem Cells
Abstract:Cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for 31% of all deaths globally. Myocardial ischemia-reperfusion injury (IRI), a common complication of CVDs, is a major cause of mortality and morbidity. Studies have shown efficacious use of mesenchymal stem cells-derived extracellular vesicles (MSCs-EVs) to mitigate IRI in animals, but few research has been done on human-related models. In this study, human embryonic stem cell-derived chambered cardiac organoid (CCOs) was used as a model system to study the effects of MSC-derived small extracellular vesicles (sEVs) on myocardial IRI. The results revealed that MSC-sEVs treatment reduced apoptosis and improved contraction resumption of the CCOs. Metabolomics analysis showed that this effect could be attributed to sEVs' ability to prevent the accumulation of unsaturated very long chain fatty acids (VLCFAs). This was corroborated when inhibition of fatty acid synthase (FASN), which was reported to reduce VLCFAs, produced a similar protective effect to sEVs. Overall, this study uncovered the mechanistic role of sEVs in mitigating IRI that involves preventing the accumulation of unsaturated VLCFA, decreasing cell death, and improving contraction resumption in CCOs.
oncology,cell biology,hematology,biotechnology & applied microbiology,cell & tissue engineering
What problem does this paper attempt to address?